Showing results (1-10 of 737) with videos related to
Sort By:
Pageof 74
Scientific Reports|June 2, 2025
Potential surrogate endpoint for B-cell hematologic malignancy: A systematic review and meta-analysisSatoshi Hirano, Keisuke Hanada, Hideki MaedaJournal of Biopharmaceutical Statistics|April 16, 2026
Random effect restricted mean survival time modelKeisuke Hanada, Masahiro KojimaClinical Pharmacology and Therapeutics|May 25, 2021
Japan's Special Approval for Emergency System During the COVID-19 PandemicHideki MaedaFrontiers in Medicine|January 31, 2022
The Current Status and Future Direction of Clinical Research in Japan From a Regulatory PerspectiveHideki MaedaFrontiers in Medicine|August 26, 2021
Medical Affairs in Pharmaceutical Companies and Related Pharmaceutical Regulations in JapanHideki MaedaOrganic Letters|December 6, 2002
The stereocontrolled total synthesis of (-)-O-methylpallidinineKeisuke Hanada, Norio Miyazawa, Kunio OgasawaraChemical & Pharmaceutical Bulletin|January 10, 2003
A new route to (+)-estrone using a bicyclo[3.2.1]octane chiral building blockKeisuke Hanada, Norio Miyazawa, Kunio OgasawaraContemporary Clinical Trials|January 16, 2024
Comparison of baseline covariate adjustment methods for restricted mean survival timeKeisuke Hanada, Junji Moriya, Masahiro KojimaJournal of Clinical Pharmacology|January 7, 2015
Regulatory review time for approval of oncology drugs in Japan between 2001 and 2014. Considerations of changes, factors that affect review time, and difference with the United StatesHideki Maeda, Tatsuo KurokawaGan to Kagaku Ryoho. Cancer & Chemotherapy|August 19, 2014
[Enzalutamide-a novel androgen receptor inhibitor that provides treatment options for patients with castration-resistant prostate cancer]Hideki Maeda, Atsushi SaitoPageof 74